X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Tranexamic acid oral rinse is a USFDA approved antifibrinolytic agent, plasminogen inhibitor, which is being evaluatd in phase 3 clinical trials for the treatment of dental bleeding.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Dental and Oral Health Product Name: Tranexamic Acid Oral Rinse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
LB1148 (tranexamic acid) is a broad-spectrum serine protease inhibitor that has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: LB1148
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Details:
LB1148 (tranexamic acid) is a broad-spectrum serine protease inhibitor that has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2023
Details:
LB1148 (tranexamic acid), is a broad-spectrum serine protease inhibitor that has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
LB1148 (tranexamic acid), is a broad-spectrum serine protease inhibitor that has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
LB1148 (tranexamic Acid), is a broad-spectrum serine protease inhibitor that has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2023
Details:
LB1148 (tranexamic acid) is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. It is being investigated to accelerate the return of bowel function following abdominal surgery.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Newsoara Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2023
Details:
In clinical studies, LB1148 (tranexamic acid) has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2022
Details:
The oral presentation will include new GI functional data sub-cuts from highly statistically significant Phase 2 clinical study demonstrating LB1148 (tranexamic acid) accelerated the return of post-operative GI function in patients undergoing elective bowel resection.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2022
Details:
Company is conducting an ongoing randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 2 clinical trial of LB1148 (tranexamic acid) in up to 200 patients undergoing elective bowel resection surgery.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Details:
LB1148, the company’s lead asset in development, is a novel oral liquid formulation of the well-characterized digestive enzyme inhibitor tranexamic acid, with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2022
Details:
Company plans to use the net proceeds to us from this offering primarily for general corporate purposes, including research and development of pipeline products including LB1148 (tranexamic acid) and working capital.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ladenburg Thalmann & Co.
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 12, 2022
Details:
LB1148, is a novel oral liquid formulation of the well-characterized digestive enzyme inhibitor, tranexamic acid (“TXA”), with potential to both reduce abdominal adhesions and help restore bowel function following surgery.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
LB1148 (tranexamic acid) is an oral formulation serine protease inhibitor designed to neutralize activity of potent digestive proteases released from gut during surgery, to prevent damage to GI tissues, accelerate time to return of normal GI function.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2022
Details:
HY-004, an antifibrinolytic agent, tranexamic acid, as an oral mouth rinse proprietary formulation (Tranexamic Acid Oral Solution, 5%) in healthy patients following tooth extraction.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: HY-004
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
Details:
In multiple clinical studies, LB1148 has demonstrated statistically significant acceleration in the time to the return of normal GI function, and has the potential to prevent damage to GI tissues and shorten the duration of costly post-surgery hospital stays.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
LB1148 (tranexamic acid), is an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Newsoara
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2022
Details:
In two separate Phase 2 trials—one in cardiovascular surgery patients and one in GI surgery patients —LB1148, an serine protease inhibitor has demonstrated statistically significant acceleration of return of GI function.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
LB1148 is an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
LB1148, serine protease inhibitor designed to neutralize activity of potent digestive proteases released from the gut during surgery, also prevent damage to GI tissues, accelerate time to return normal GI function, and shorten duration of costly post-surgery hospital stays.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2022
Details:
Issuance of Additional U.S. Patent to Company Continues to Advance LB1148, for use in treating adhesions and postoperative ileus is a major milestone for GI surgery patients.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2021
Details:
Under the agreement, Amring granted to Pierre Fabre an exclusive license to exploit and commercialize LYSTEDA (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB) in Mexico.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Lysteda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Amring Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 29, 2021
Details:
The funds will be used to advance the clinical development of Palisade's lead oral liquid drug candidate LB1148, which is being developed to accelerate the return of bowel function after surgery and to reduce post‐surgical adhesions.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Yuma Regional Medical Center
Deal Size: $5.2 million Upfront Cash: Undisclosed
Deal Type: Funding August 20, 2021
Details:
The PROFILE study is a randomized, double-blind, multicenter, Phase 2 trial expected to enroll 120-200 patients undergoing elective bowel resection at 11 sites across the U.S. Patients received a single oral dose of LB1148 prior to surgery.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2021
Details:
Palisade Bio will focus on developing therapeutics for broad GI disorders and complications. LB1148, is a patent-protected oral formulation of a protease inhibitor that neutralizes the activity of digestive proteases released from the gut during surgery.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Product Name: LB1148
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Palisade Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger April 27, 2021
Details:
Acquisition of the global rights to LYSTEDA® (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB), will further strengthen Amring's position in the marketplace.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Lysteda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Amring Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 02, 2020
Details:
The primary objective of this study is to determine whether oral/enteral administration of liquid LB1148 will impact disease progression in hospitalized patients with moderate-to-severe COVID-19 infection.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
The company believes LB1148 mechanism of action may limit the viral load in patients with COVID-19 as the SARS-CoV-2 virus uses the ACE2 receptor, which is highly expressed in the lung and GI tract.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2020
Details:
Data demonstrate efficacy on an approvable endpoint that may also result in substantial cost savings based on reductions ICU and hospital length of stay.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
